Associated Papers
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Khouja M et al.
Leukemia, 2026
41184633 (PubMed )
Supplement: 41375_2025_2787_MOESM2_ESM.xlsx › Table_S5
A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays.
Galbo PM et al.
The Journal of Molecular Diagnostics : Jmd, 2025
40158885 (PubMed )
Supplement: mmc8.xlsx › Sheet1
Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.
Lang JD et al.
Biomarker Research, 2023
37491309 (PubMed )
Supplement: 40364_2023_511_MOESM16_ESM.xlsx › 01TL
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Gángó A et al.
International Journal of Cancer, 2020
NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
D'Agaro T et al.
British Journal of Haematology, 2018
Genomic landscape of salivary gland tumors.
Kato S et al.
Oncotarget, 2015
26247885 (PubMed )
Supplement: oncotarget-06-25631-s002.xlsx › Sheet1
Select a paper to view details